- By ICR Secretariat
- Posted Wednesday, November 20, 2019
NICE ‘OK’ for Sativex in MS
The National Institute for Health and Care Excellence (NICE) has recommended Bayer’s Sativex (delta-9 tetrahydrocannabinol (THC) cannabidiol (CBD)), for spasticity in people with multiple sclerosis (MS).
The cannabis-based medicinal product has been approved within its licensed indication, as the organisation deemed it clinically and cost effective at its current list price. NICE also updated the MS Guideline to state that Sativex should be offered to treat spasticity in people with the disorder.